Related references
Note: Only part of the references are listed.Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients
Kathryn Clarkston et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease
Karen van Hoeve et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
Amy Hemperly et al.
CLINICAL PHARMACOKINETICS (2018)
Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease
Tomer Greener et al.
INFLAMMATORY BOWEL DISEASES (2018)
Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases
Bella Ungar et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience
Jennifer C. deBruyn et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Success and safety of high infliximab trough levels in inflammatory bowel disease
David Drobne et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
JOURNAL OF CROHNS & COLITIS (2018)
Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
Laura Merras-Salmio et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease
Adam Frymoyer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)
Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors
Jan Ohem et al.
DIGESTIVE DISEASES (2017)
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease
A. J. Yarur et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease
Karin Malickova et al.
BIOLOGICALS (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease
Adam Frymoyer et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2016)
Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
Joana Afonso et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD
Naamah L. Zitomersky et al.
INFLAMMATORY BOWEL DISEASES (2015)
Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2015)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
Namita Singh et al.
INFLAMMATORY BOWEL DISEASES (2014)
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
F. M. Ruemmele et al.
JOURNAL OF CROHNS & COLITIS (2014)
Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger
Judith R. Kelsen et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2014)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Rational development and utilization of antibody-based therapeutic proteins in pediatrics
Zhenhua Xu et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
N. Vande Casteele et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease: The Paris Classification
Arie Levine et al.
INFLAMMATORY BOWEL DISEASES (2011)
Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity
Johanna Haapamaki et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Share Paper
